/INRLF
INRLF Stock - Valneva SE
Healthcare|BiotechnologyOTC
$4.27+0.00%
+$0.00 (+0.00%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.54
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.69
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $4.70
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INRLF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.23 – $4.31
TARGET (TP)$4.91
STOP LOSS$3.93
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.28
52W High$6.28
52W Low$1.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $169.58M | $153.71M | $361.30M | $348.08M | $110.32M |
| Gross Profit | $71.04M | $52.84M | $36.86M | $160.16M | $56.02M |
| Gross Margin | 41.9% | 34.4% | 10.2% | 46.0% | 50.8% |
| Operating Income | $13.33M | $-82,087,000 | $-113,443,000 | $-61,390,000 | $-55,120,000 |
| Net Income | $-12,247,000 | $-101,429,000 | $-143,279,000 | $-73,425,000 | $-64,393,000 |
| Net Margin | -7.2% | -66.0% | -39.7% | -21.1% | -58.4% |
| EPS | $-0.09 | $-0.73 | $-1.24 | $-0.75 | $-0.71 |
Company Overview
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
INRLFBeat Rate
37%
Last 19 quarters
Avg Surprise
-73.8%
EPS vs Estimate
Beats / Misses
7/12
Last 12 quarters
Latest EPS
$-0.50
Q4 2025
EPS Surprise History
Q1 24
-632.8%
$-0.25vs$0.05
Q2 24
-19.0%
$0.46vs$0.56
Q3 24
-21.0%
$-0.20vs$-0.17
Q4 24
+43.3%
$-0.08vs$-0.14
Q1 25
-212.3%
$-0.29vs$-0.09
Q2 25
+51.5%
$-0.07vs$-0.14
Q3 25
+45.7%
$-0.09vs$-0.16
Q4 25
-174.3%
$-0.50vs$-0.18
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 18, 2026 | — | — | — | — |
Q4 2025 | Nov 20, 2025 | $-0.18 | $-0.50 | -174.3% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.16 | $-0.09 | +45.7% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.14 | $-0.07 | +51.5% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.09 | $-0.29 | -212.3% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.14 | $-0.08 | +43.3% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.17 | $-0.20 | -21.0% | ✗ MISS |
Q2 2024 | May 7, 2024 | $0.56 | $0.46 | -19.0% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $0.05 | $-0.25 | -632.8% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-0.22 | $-0.26 | -16.2% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-0.13 | $-0.13 | +0.5% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.19 | $-0.14 | +25.6% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $0.16 | $-0.32 | -300.0% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $0.78 | $0.66 | -15.4% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.34 | $-1.34 | -294.1% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.31 | $-0.24 | +22.6% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-0.35 | $1.94 | +654.3% | ✓ BEAT |
Q4 2021 | Nov 18, 2021 | $-0.50 | $-1.85 | -270.7% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.39 | $-0.61 | -56.4% | ✗ MISS |
Q2 2021 | May 20, 2021 | $-0.09 | $-0.30 | -233.3% | ✗ MISS |
Latest News
Valneva shares are trading higher after the company announced final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The company also announced its plans to concentrate its French operations at its Lyon location, closing the site in Nantes.
📈 PositiveBenzinga•Nov 26, 2025, 04:35 PM•Also:
Valneva Plans To Close Facilities In Nantes, France, To Consolidate Operations At Lyon Site
➖ NeutralBenzinga•Nov 26, 2025, 04:31 PM•Also:
Valneva Announced Positive Final Immunogenicity And Safety Data From Phase 2 Study, VLA15-221, Of Lyme Disease Vaccine Candidate, VLA15
📈 PositiveBenzinga•Nov 26, 2025, 08:25 AM•Also:
Valneva Q3 EPS $(0.61) Misses $(0.30) Estimate, Sales $34.386M Miss $50.250M Estimate
📉 NegativeBenzinga•Nov 20, 2025, 10:26 PM•Also:
Valneva Nine Months 2025 EPS €(0.39) Down From €0.17 YoY, Revenue €126.97M Up From €116.6M YoY
➖ NeutralBenzinga•Nov 20, 2025, 06:13 AM•Also:
Valneva Reports Phase 1 Results Demonstrating Improved Immune Response For Second-Generation Zika Vaccine Candidate VLA1601
📈 PositiveBenzinga•Nov 4, 2025, 06:57 AM•Also:
Valneva Secures Up To $500M Non-Dilutive Debt Facility; Lowers FY25 Total Revenue Guidance From €180 Million - €190 Million To €165 Million - €180 Million
➖ NeutralBenzinga•Oct 6, 2025, 03:38 PM•Also:
Valneva's IXCHIQ Shows 95% Antibody Seroresponse Sustained Four Years After Single Dose In Adults Aged 18 To 65+
📈 PositiveBenzinga•Sep 30, 2025, 05:25 AM•Also:
Guggenheim Maintains Buy on Valneva, Lowers Price Target to $13
➖ NeutralBenzinga•Sep 8, 2025, 01:51 PM•Also:
Valneva Lyme Vaccine Candidate VLA15 Demonstrates Strong Anamnestic Response And Favorable Safety Profile After Third Yearly Booster Dose
📈 PositiveBenzinga•Sep 3, 2025, 06:14 AM•Also:
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $18 Price Target
📈 PositiveBenzinga•Aug 25, 2025, 05:56 PM•Also:
Valneva shares are trading lower after the FDA suspended the license for IXCHIQ.
📉 NegativeBenzinga•Aug 25, 2025, 01:04 PM•Also:
Valneva Announces FDA Suspension Of IXCHIQ License In United States Following Four New Serious Adverse Events Reports
📉 NegativeBenzinga•Aug 25, 2025, 05:46 AM•Also:
HC Wainwright & Co. Assumes Valneva at Buy, Announces Price Target of $18
📈 PositiveBenzinga•Aug 19, 2025, 11:10 AM•Also:
Valneva's Single-Dose Chikungunya Vaccine IXCHIQ Secures Health Canada Authorization For Individuals Aged 12 Years And Older
📈 PositiveBenzinga•Aug 18, 2025, 05:36 AM•Also:
Frequently Asked Questions about INRLF
What is INRLF's current stock price?
Valneva SE (INRLF) is currently trading at $4.27 per share. The stock has moved +0.00% today.
What is the analyst price target for INRLF?
No analyst price targets are currently available for this stock.
What sector is Valneva SE in?
Valneva SE operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is INRLF's market cap?
Valneva SE has a market capitalization of $0.73 billion, making it a small-cap company.
Does INRLF pay dividends?
No, Valneva SE does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAVCTF
Avacta Group Plc
$1.11
Mkt Cap: $0.5B
BPMUF
Basilea Pharmaceutica AG
$63.25
Mkt Cap: $0.8B
ELEAF
EL.En. S.p.A.
$12.52
Mkt Cap: $1.0B
GSGTF
GenSight Biologics S.A.
$0.19
Mkt Cap: $0.0B
IDRSF
Idorsia Ltd
$4.80
Mkt Cap: $1.1B
MDCLF
MedinCell S.A.
$6.98
Mkt Cap: $0.2B
MDRX
Veradigm Inc.
$4.83
Mkt Cap: $0.8B
SAFLF
Safilo Group S.p.A.
$2.20
Mkt Cap: $0.9B
SOLTF
Nxera Pharma Co., Ltd.
$5.34
Mkt Cap: $0.5B
VBIZF
Viva Biotech Holdings
$0.25
Mkt Cap: $0.5B
Explore stocks similar to INRLF for comparison